COMMERCIAL MANUFACTURING AGREEMENT InterMune, Inc., Pirfenidone CapsulesCommercial Manufacturing Agreement • March 15th, 2010 • Intermune Inc • Pharmaceutical preparations • New York
This Commercial Manufacturing Agreement (“Agreement”) is made as of this 10th day of September, 2009 (“Effective Date”), by and between InterMune, Inc., a Delaware corporation, with a place of business at 3280 Bayshore Blvd., Brisbane, CA 94005 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873 (“Catalent”).
SECOND AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • March 15th, 2010 • Intermune Inc • Pharmaceutical preparations
This Second Amendment (“Second Amendment”) to the Exclusive License and Collaboration Agreement effective as of October 16, 2006 (as amended by that certain First Amendment effective as of October 16, 2008 (“First Amendment”)) (collectively, the “Agreement”) is made effective as of October 16, 2009 (the “Second Amendment Effective Date”) and entered into by and between Hoffmann-La Roche Inc., a New Jersey corporation located at 340 Kingsland Street, Nutley, New Jersey 07110 (“Roche Nutley”), and F.Hoffmann-La Roche Ltd, a Swiss corporation, with its principal office at Grenzacherstrasse 124, CH-4070 Basel, Switzerland (“Roche Basel”; Roche Nutley and Roche Basel are collectively referred to as “Roche”), on the one hand, and InterMune, Inc., a Delaware corporation with its principal place of business at 3280 Bayshore Boulevard, Brisbane, California 94005 (“InterMune”), on the other hand.
